- Home
- WGSWW vs XOMAP Comparison
WGSWW vs XOMAP Comparison
Compare WGSWW & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGSWW
- XOMAP
- Stock Information
- Founded
- WGSWW 2017
- XOMAP N/A
- Country
- WGSWW United States
- XOMAP United States
- Employees
- WGSWW N/A
- XOMAP 13
- Industry
- WGSWW Retail: Computer Software & Peripheral Equipment
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- WGSWW Technology
- XOMAP Health Care
- Exchange
- WGSWW Nasdaq
- XOMAP Nasdaq
- Market Cap
- WGSWW N/A
- XOMAP N/A
- IPO Year
- WGSWW N/A
- XOMAP N/A
- Fundamental
- Price
- WGSWW $0.25
- XOMAP $25.62
- Analyst Decision
- WGSWW
- XOMAP
- Analyst Count
- WGSWW 0
- XOMAP 0
- Target Price
- WGSWW N/A
- XOMAP N/A
- AVG Volume (30 Days)
- WGSWW 35.4K
- XOMAP N/A
- Earning Date
- WGSWW 02-18-2025
- XOMAP N/A
- Dividend Yield
- WGSWW N/A
- XOMAP N/A
- EPS Growth
- WGSWW N/A
- XOMAP N/A
- EPS
- WGSWW N/A
- XOMAP N/A
- Revenue
- WGSWW $305,450,000.00
- XOMAP N/A
- Revenue This Year
- WGSWW N/A
- XOMAP N/A
- Revenue Next Year
- WGSWW N/A
- XOMAP N/A
- P/E Ratio
- WGSWW N/A
- XOMAP N/A
- Revenue Growth
- WGSWW 50.79
- XOMAP N/A
- 52 Week Low
- WGSWW $0.21
- XOMAP N/A
- 52 Week High
- WGSWW $0.25
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- WGSWW N/A
- XOMAP 47.68
- Support Level
- WGSWW N/A
- XOMAP $25.57
- Resistance Level
- WGSWW N/A
- XOMAP $25.83
- Average True Range (ATR)
- WGSWW 0.00
- XOMAP 0.11
- MACD
- WGSWW 0.00
- XOMAP -0.01
- Stochastic Oscillator
- WGSWW 0.00
- XOMAP 24.24
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.